Presented by
Management Forum
This comprehensive course has been designed to map the processes from device concept to marketing and show how regulatory, quality, clinical and other aspects of device development are joined into a continuous process.
★★★★★ "Very good, I achieved what I set out to do at the beginning of the week."
Bringing a medical device to the marketplace is a complex and lengthy procedure which requires experience, knowledge and specialist skills. The contribution to successful market placement comes from many different skilled individuals and organisations who should be aware of all the stages involved and be able to relate their responsibilities to the needs of other professionals, scientists, clinicians and regulatory and quality experts.
This comprehensive course has been designed to map the processes from device concept to marketing and show how regulatory, quality, clinical and other aspects of device development are joined into a continuous process. The programme will commence with a general introduction as to what devices are and how they are developed, and continue with lectures, practical workshops and case studies covering each process applicable to device development, marketing and, eventually, postmarket procedures. There will be ample time throughout the five days for informal discussions
with our expert faculty and fellow professionals.
Benefits of attending:
Understand the procedures for taking a medical device to the marketplaceThis course is of our range of Medical Devices training courses - now also including Medical Devices Cyber Security training to help improve your data security.
This event has been designed primarily for those who wish to understand the processes involved in bringing a medical device to market. General medical devices as well as active implantable, in-vitro diagnostic and drug device products will be covered in the programme.
The course will be of particular interest to those seeking to introduce new medical devices to the market. Previous delegates who have benefited include regulatory, quality, clinical and marketing managers.
Key positions held in career
Programme Director Translucency Ltd
Director of Operations Quintiles Consulting, specialising in medical device reimbursement
Marketing Director Howmedica International (at the time a Pfizer company) manufacturing orthopaedic implants
Group Product Manager Amersham International (now part of GE healthcare). Launch of novel IVD platform
Major areas of expertise
Experience across a wide range of medical technologies
Business planning
Market assessment
Product management
Services offered through Translucency
Early commercialisation
Market access
Product reimbursement
Management of multi-country projects
Educational and professional achievements
PhD in Public Health
MA in Natural Sciences (specialist subject biochemistry)
MSc in Information Science
Member of the Chartered Institute of Marketing
Speaker on medical device reimbursement at conferences
Janette Benaddi is a business mentor, international speaker/trainer and consultant to the medical device industry. Janette has over 25 years’ experience of managing pre and post market clinical studies in both devices and pharmaceuticals. Janette has worked with several multinational organizations in various clinical, regulatory and marketing roles.
She has extensive experience of conducting clinical studies with medical device products as well as regulatory expertise for CE marking of devices. Specifically she has been involved in writing and reviewing hundreds of Clinical evaluation reports for the medical device industry, she has also provided training to Notified bodies in this subject.
Janette qualified as a registered nurse in 1984, she has a BSc in Management studies, a Diploma in Company Direction, and a Diploma in Management studies, holds a teaching certificate and is a Chartered Scientist and Chartered Director. Janette sits on several committees in the device community and industry and has been an instrumental advocate of improving and advancing medical device research in the UK. Janette has published several articles relating to medical device regulation and clinical studies.
Theresa works for SFL as Head of Combination Products. Theresa has over 25 years’ experience working in both the Pharmaceutical and Medical Device industries and has worked in a variety of roles across the full development cycle from product concept and early stage development, process transfer, validation and regulatory departments, and has been a part of the team for many commercially available medicinal and medical device products.
Zuzanna Kwade is Software Clinical Evaluation Lead at Dedalus Healthcare. Zuzanna holds a PhD in Biochemistry and has 15 years of experience in clinical and medical research. She is the co-author of several white papers on regulatory aspects of clinical research and clinical evaluation.
Since 2016, she has been actively involved in Clinical Evaluations according to MEDDEV 2.7.1 (Rev.4) for multiple devices, including high risk hardware devices and medical software. She also represented COCIR in the European Union Task Force on clinical evaluation of software and co-authored MDCG2020-1 guidance on clinical evaluation of MDSW.
Adrian Keene is Director, Product Development Strategy at NAMSA, where he utilises his broad experience of changing EU medical device regulatory requirements to support clients worldwide. He was previously Head of Notified Body for the UK Notified Body SGS. Prior to that he was Global Clinical Affairs and Regulatory Manager for Medical Devices, with responsibility for conformity assessment activities of high risk (class III) devices under the Medical Devices Directive.
In this role he combines his experience from new product development with EU regulatory requirements to provide a balanced interpretation of the needs and expectations of both competent authorities and manufacturers. He works with a broad range of devices including drug-device combination products.
Adrian has 25 years experience in the medical device industry, and previously held the role of Technical Manager – Medical Devices at the Notified Body LRQA. Prior to that he worked in the medical device industry, latterly as Global Product Safety Manager at Smith and Nephew. Here he created a highly effective team delivering product safety and risk management to Smith and Nephew’s global wound management portfolio. His team was responsible for providing toxicological and risk management strategies to expedite product launches, commercialisation, and post market activities, including Far Eastern markets (Japan and Korea).
He joined Smith & Nephew directly from The School of Pharmacy (University of London) following postgraduate research in retinoid-induced skeletal toxicity and an honours degree in Toxicology and Pharmacology. He also holds a Diploma in Managing Medical Product Innovation from the Scandinavian International Management Institute.
Adrian is a UK expert for ISO/TC 194 (Biological Evaluation of Medical Devices), and has been an active participant in NB-MED and NBRG.
Will is currently the Director of Russell Square Quality Representatives (RSQR) Ltd. He is engaged in providing a range of consultancy and training services to the international medical device, pharmaceutical and biotechnology industry sectors. Prior to founding RSQA in 1995, Will was the Professional Services Manager of the Manufacturer Registration Scheme Business Unit of the UK Medical Devices Agency (now MHRA).
In 2003 David established PharmaDelivery Solutions Ltd as a specialised consultancy service in the field of drug delivery combination products (especially respiratory) device technology. This has led to involvement in projects with focus in pulmonary, nasal and other delivery routes, with an international client base. Much of the activity of PharmaDelivery Solutions Ltd is focused in the area of development programme support, regulatory GAP analysis and generation of documentation supporting development and test programmes, together with data review and contingency evaluation.
David has over 35 years experience in the development, industrialization and approval of inhalation drug delivery systems, combination products and medical devices.
Stuart Angell is a joint director in his own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.
He has over 15 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex list II products including technical documentation for EU and global submissions (FDA, Health Canada, TGA, Russia, Latin America). He has an excellent understanding of risk management, Post Market Surveillance (PMS) and vigilance.
Very good, I achieved what I set out to do at the beginning of the week.
Jun 12 2023
Natasha Smith
Marketing Director, Bedfont Scientific Ltd
Jun 12 2023
Really engaging and focused on the EU. Enjoyed the fact this was current and mentioned up to date legislation and regulation updates.
Chelsey Ludlow
Regulatory Affairs Coordinator, Vision RT Ltd
Jun 12 2023
Speaker are very good and expert in their area
Lutfhi Zarkasyi
Plant Head, PT. Forsta Kalmedic Global
Jun 12 2023
I really enjoyed the workshops as it gave the opportunity to interact with the other delegates on the course and discuss and develop learnings from the presentations.
Emma Hickson
Research Advisor, Convatec
Jun 12 2023
excellent
Lutfhi Zarkasyi
Plant Head, PT. Forsta Kalmedic Global
Jun 12 2023
I particularly enjoyed the break out rooms as this gave you time to have discussions with other attendees and it broke up the presentations which aided concentration.
Samantha Hutchinson
Research Advisor, Convatec Ltd
Jun 13 2022
They all delivered their subjects well; especially Janette Benaddi... 10/10
Anthonia Oluwatuyi
Quality Graduate, Bespak Europe Limited
Jun 13 2022
Overall, I loved all speakers. They all did an excellent job. I really liked the way Janette was structuring her talks with a lot of interactive questions and quizzes. That helped me in capturing the content better... Very good - would definitely recommend it.
Chloë Scheldeman
R&D Manager Scientific Development, 2 Bridge
Jul 1 2019
A very well structured course with a logical progression through the regulations. The speakers aimed their knowledge at the right level.
Richard Oliver
Head of Technical and Clinical, STD Pharmaceutical Products Ltd
Jul 1 2019
The whole structure has been put together very well.
Dipti Patel
Cunsultant, SGR Consulting Services Ltd
Jul 2 2018
All speakers were really good, they captured my attention from the very first slide. Their presentations had a clear structure and easy to follow.
Cristina Stanca
Senior CMC specialist, Pharmedd Services Ltd
Jul 2 2018
Good clear presentations and great interactive sessions. Very informative and interesting. It was a fun learning experience.
Catherine Sutherland
Director, Drug Development Operations, Allergan Ltd
Jul 2 2018
Informative and interactive
Paridhi Dubey
Regulatory Affairs Coordinator, Cochlear Ltd
Jul 3 2017
Greta, informative, well educated
Abdulrahman Al Saeed
Saudi Food and Drug Authority
Jul 3 2017
The course helped to structuralize the knowledge on the regulatory requirements and helps to understand where each piece of the puzzle fits in. It was a very useful course to take.
Santa Popova
Quality Control Manager , Light Guide Optics International
Jul 3 2017
The course helps to make sense of the requirements of MDD and MDR. I liked that both MDD and MDR were covered
Santa Popova
Quality Control Manager , Light Guide Optics International
Jul 3 2017
Overall it was an outstanding course - very specialist speakers but in some topics they should go deeper into details.
Abdulielah Al Mutairi
Senior Biomedical Engineer, Saudi Food and Drug Authority
Jul 4 2016
It was pretty good and helpful
Hadi Dhafer AlShehri
Registration and Licensing Specialist , Saudi Food and Drug Authority
Jul 4 2016
Excellent course for getting all the basic concepts
Anne Møller Nielsen
IMM, Novo Nordisk
Jul 4 2016
Very professional but also personable
Susan Fotheringham
Principal Scientist, Oxford Cancer Biomarkers
Jul 4 2016
Great course and much information to digest now. Speakers were all very good and experienced within their subject.
Jes Schmidt-Petersen
Global Regulatory Affairs Manager, Ferring Pharmaceuticals A/S
United Kingdom
Denmark
Switzerland
Italy
Germany
Netherlands
Belgium
United States of America
Finland
France
South Africa
Spain
Sweden
Austria
Czech Republic
Indonesia
Japan
Latvia
Portugal
Saudi Arabia
Singapore
United Arab Emirates
5 days
Typical duration
Pricing from:
We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.
Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:
Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to: